Book a meeting
DO-BO

Europe vs. US: Who Leads the Future of Market Access, Dr. Doug Niven?

In this thought-provoking episode of MAP, the Market Access Podcast, Dr. Stefan Walzer sits down with strategic Market Access consultant Dr. Doug Niven to explore one of the most pressing questions in pharma today – can Europe maintain its leadership in Market Access, or is it falling behind? 

From joint HTA (JCA), pricing reforms, and AI-driven tools to global value frameworks and real-world data, this episode unpacks key trends shaping pharma, biotech, and healthcare access in 2025 and beyond. If you’re in health economics, pricing & reimbursement, or regulatory strategy, this is a must-listen.

Related

Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel?

By

Stefan Walzer

In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former Head of the Medical Devices Division at Swissmedic – to unpack how regulation and market access truly fit together. They discuss why medical device regulation in Europe […]

From Necessary Tasks to New Insights: How Can AI Act as a Sparring Partner in Market Access, Helmut Butscher?

By

Stefan Walzer

In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Access value chain. They explore how AI accelerates systematic literature reviews, unlocks real‑world evidence from complex data sources, supports HTA dossier preparation, and enables smarter decisions on pricing, reimbursement and global launch sequencing. They […]

Can Innovative Contracting Turn High‑Cost Therapies into Sustainable Deals, Omar Ali?

By

Stefan Walzer

In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE advisor, and one of the sharpest minds in drug pricing and innovative contracting to unpack where drug pricing and reimbursement are really heading.  They explore why cost‑effectiveness thresholds are making market access […]